Lorlatinib use in an infant with thalamic ALK-positive histiocytosis
Pediatr Blood Cancer
.
2023 Apr 19:e30378.
doi: 10.1002/pbc.30378.
Online ahead of print.
Authors
Irem Eldem
1
,
Jennifer Picarsic
2
,
Ashish Kumar
3
4
,
Yaël P Mossé
5
6
,
Kaleigh Filisa Roberts
7
,
Amy E Armstrong
1
,
Bryan A Sisk
1
8
Affiliations
1
Division of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri, USA.
2
Division of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
3
Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
4
University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
5
Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
6
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
7
Division of Neuropathology, Department of Pathology & Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
8
Bioethics Research Center, Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA.
PMID:
37073762
DOI:
10.1002/pbc.30378
No abstract available
Publication types
Letter